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Urokinase-type plasminogen activator (uPA) participates in cancer-related biologic processes, such aswound healing and
inflammation. The present study aimed to investigate the effect of uPA deficiency on the long-term outcome of early life
episodes of dextran sodiumsulfate (DSS)–induced colitis inmice.Wild-type (WT) and uPA-deficient (uPA−/−) BALB/cmice
were treated with DSS or remained untreated. Mice were necropsied either 1 week or 7 months after DSS treatment.
Colon sampleswere analyzed by histopathology, immunohistochemistry, ELISA, and real-time polymerase chain reaction.
At 7months, with no colitis evident, half of the uPA−/−mice had large colonic polypoid adenomas, whereasWTmice did
not. One week after DSS treatment, there were typical DSS-induced colitis lesions in both WT and uPA−/− mice. The
affected colon of uPA−/−mice, however, had features of delayed ulcer re-epithelialization and dysplastic lesions of higher
grade developing on the basis of a significantly alteredmucosal inflammatorymilieu. The later was characterized bymore
neutrophils andmacrophages, less regulatory T cells (Treg), significantly upregulated cytokines, including interleukin-6
(IL-6), IL-17, tumor necrosis factor-α, and IL-10, and lower levels of active transforming growth factor–β1 (TGF-β1)
compared toWTmice. Dysfunctional Treg,more robust protumorigenic inflammatory events, and an inherited inability
to produce adequate amounts of extracellular active TGF-β1 due to uPA deficiency are interlinked as probable
explanations for the inflammatory-induced neoplasmatogenesis in the colon of uPA−/− mice.
Translational Oncology (2014) 7, 174–187.e5Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
4 (to S.E.E.).
W2 and Figures W1 to W4 and are available online at http://www.transonc.com.
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Accumulating evidence suggests that cells and factors of the tumor
microenvironment contribute decisively not only to the survival of
primary neoplastic cells but also to subsequent key events of
neoplastic disease progression including tumor growth, invasion,
and metastasis [1-3]. Various and many times interrelated de-
terminants govern this complex tumor-host interaction; among them
inflammatory and proteolytic-related phenomena have been shown to
be particularly important [4-8]. It is now well accepted that chronic
inflammation may lead to tumorigenesis [4,7,9]. Several lines of
evidence, however, show that all neoplasms, not just those arising on
the background of chronic inflammation, thrive with inflammatory
cell stimuli. Indeed, many times the tumor elicited immune response
is unable to eliminate a rapidly growing population of cells that is
always one step ahead due to the natural selection advantage. Instead,
it shapes the tumor stroma in favor of cancer cell survival and
expansion in a manner similar to that observed in tissue remodeling
and repair [2,3,6,7]. In that sense, the view of cancer as “a wound that
does not heal” [10] has been further solidified. Consequently, key
regulators of wound healing, such as immune cells and proteases, are
now recognized as fundamental rather than secondary players in
neoplasmatogenesis [3].
One such regulator is urokinase-type plasminogen activator (uPA),
a protease that has a dominant role in the proteolytic network and is
primarily involved in fibrinolysis, tissue remodeling, and cell
migration [11-14]. uPA catalyzes the conversion of plasminogen to
plasmin and also activates other important proteases, including
cathepsin B and matrix metalloproteinases. The targets of uPA in turn
activate an array of proteins with a broad spectrum of biologic
activities [13,14]. In the tumor microenvironment, the complex
cascades initiated by uPA promote tumor progression. First, they
facilitate neoplastic cell invasion, motility, and metastasis by
degrading epithelial basement membranes and the extracellular
matrix. Second, they support tumor growth by stroma remodeling
and angiogenesis. Finally, they are involved in proliferating and
antiapoptotic tumor cell signaling [8,14-18]. These facts, supported
by many studies in both animal models [19-24] and humans [15,25],
have placed uPA among the tumor promoting molecules with
emerging importance. To date, uPA is considered as a poor prognosis
factor and a potential therapeutic target for most types of cancer
including colorectal cancer [15,25,26].
Transforming growth factor–β1 (TGF-β1) is one of the most
important factors activated by the uPA-generated plasmin [14,27].
TGF-β1 is ubiquitously produced by a variety of cells and excreted in
the extracellular matrix in a latent form. The cleavage of this form by
plasmin results in the production of the biologically active TGF-β1
[28], which has been shown to act as a tumor suppressor in the early
stages of tumor development and as a major regulator of immune
events in the tumor microenvironment [29,30]. As with the
corruption of normal TGF-β1 signaling pathways at the gene level
[29,30], the lack of extracellular active TGF-β1 protein may also
increase the risk of cancer initiation. Following this reasoning, we
hypothesized that uPA and TGF-β1 may have an interlinked tumor-
suppressive function. This, however, contradicts with the current
view of uPA as a tumor promoting molecule [8,15-18].
To investigate our hypothesis, we examined the effect of uPA
deficiency on the outcome of transient episodes of dextran sodium
sulfate (DSS)–induced colitis in BALB/c mice. The DSS
administration protocol we used leads neither to overt chroniccolitis nor to colon cancer when applied to genetically intact
BALB/c mice. However, it does lead to the induction of
preneoplastic epithelial changes [31]. Using this experimental
setting, we found that the mice lacking uPA, in contrast to their
wild-type (WT) counterparts, were predisposed to adenomatous
polyp formation. The colonic epithelial preneoplasia in these mice
evolved into adenomatous polyps on the basis of a significantly
altered mucosal inflammatory milieu, which was characterized by
more neutrophils and macrophages, less regulatory T cells (Treg),
significantly upregulated cytokines, including interleukin-6 (IL-6),
IL-17, tumor necrosis factor-α (ΤΝF-α), and IL-10, and lower
levels of active TGF-β1. Our results challenge the dogma according
to which uPA is viewed solely as a tumor promoter.Materials and Methods
Animals
Specific pathogen-free certified C.129S2-Plaubtm1MlgN/J uPA-
deficient (uPA−/−) mice and background strain-matched control
BALB/cJ WT mice were purchased from Jackson Laboratories (Bar
Harbor, ME) and bred in-house to provide animals for the
experiments. Mice were kept in bio-containment facilities in static
micro-isolator cages, fed with sterilized regular mouse chow, and
given sterilized water. Helicobacter-free status of the mice was
confirmed by polymerase chain reaction (PCR) using Helicobacter
genus–specific primers in fecal and gut mucosa samples as previously
described [32]. All experimental procedures were approved by the
Faculty of Veterinary Medicine, Aristotle University of Thessaloniki
and licensed by the competent National Veterinary Administration
authorities (License No. 13/11197/11.09.08).
Experimental Design
A total of 130 (66 uPA−/− and 64 WT) male mice were used.
Experiments were performed in three replications to achieve a total
number of 11 to 24 mice per experimental group. For the induction
of chronic colitis, 3.5% DSS (molecular weight: 36-50 kDa; MP
Biomedicals Inc, Cleveland, OH) was given in the drinking water of
8- to 10-week-old mice for 1 week followed by 1 week of regular
water. This cycle was repeated three times. uPA−/− andWTmice were
either treated with DSS or remained untreated. Mice were killed
either at 7 months (first experiment—long term) or at 1 week (second
experiment—short term) after DSS treatment. Numbers of mice
per experimental group for each experiment were as follows:
first experiment: uPA−/− (n = 11), WT (n = 11), uPA−/− + DSS
(n = 11),WT + DSS (n = 11); second experiment: uPA−/− (n = 20),
WT (n = 19), uPA−/− + DSS (n = 24), WT + DSS (n = 23).
Necropsy and Tissue Sampling
Mice were killed with an overdose of isoflurane, weighted, and
necropsied. The colon of mice was then removed and cut open,
and the mucosal surface was photographed in high resolution for
grossly visible polypoid adenoma counts. One-centimeter colon
samples were collected from a standard area of the proximal part
of descending colon for gene expression and ELISA analyses.
Samples for gene expression assay were immediately immersed in
an RNA-later solution (Takara Bio Inc, Shiga, Japan) and stored
at −80°C until further processing. The remaining colon was fixed
in 10% neutral-buffered formalin for histologic and immunohis-
tochemical analyses.
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For histologic evaluation, formalin-fixed colon and mesenteric
lymph nodes (MLN) were embedded in paraffin, cut at 5 μm, and
stained with hematoxylin and eosin or immunohistochemistry (IHC).
Dysplastic and neoplastic lesions in the colonic mucosa (excluding
polyps) were scored on a 0 to 4 ascending scale using previously
described criteria [33]. Mucosal/submucosal inflammation in the
colon was scored in non-ulcerated areas based on the extent and
severity of inflammatory cell accumulations. Loss of colonic epithelial
integrity was scored on the basis of the extent and severity of the
typical DSS-induced colonic mucosal erosive and ulcerative lesions.
Both parameters were scored semi-quantitatively on 0 to 4 ascending
scales according to the following scheme: 0, normal; 1, mild; 2, mild
to moderate; 3, moderate; 4, severe.
Primary antibodies for IHC included 1) rabbit polyclonal
antibodies against β-catenin, myeloperoxidase (MPO; Thermo
Fisher Scientific/Lab Vision, Fremont, CA), E-cadherin, IL-17,
TGF-β1 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA), cleaved
caspase-3 (Cell Signaling Technology, Beverly, MA), and CD3 (Cell
Marque, Rocklin, CA); 2) rabbit monoclonal antibodies against Ki-
67 and c-kit (Cell Marque); 3) rat monoclonal antibodies against
Foxp3 (eBioscience, Inc, San Diego, CA) and F4/80 (Serotec,
Oxford, United Kingdom); and 4) a goat polyclonal antibody
against IL-16 (Santa Cruz Biotechnology, Inc). Heat-induced
antigen retrieval was performed with citrate buffer, pH 6, for β-
catenin, E-cadherin, MPO, and cleaved caspase-3, with EDTA
buffer, pH 8, for IL-17 and Foxp-3, or with CC1 epitope retrieval
solution for Ki-67, CD3, and IL-6 (Ventana Medical Systems, Inc,
Tucson, AZ). TGF-β1 antigens were retrieved with protease (Cell
Marque) and F4/80 antigens with trypsin (Thermo Fisher
Scientific/Lab Vision). Rabbit primary antibody binding was
detected with goat anti-rabbit polymer HRP (ZytoChem Plus,
Berlin, Germany), whereas rat and goat primary antibody binding
was detected with species-appropriate biotinylated secondary
antibodies (Serotec) and streptavidin-peroxidase (Ventana Medical
Systems, Inc). Color was developed with DAB substrate-chromogen
system (DakoCytomation, Glostrup, Denmark), and tissues were
counterstained with hematoxylin.
For quantitative histomorphometry, IHC-positive immune cells or
pixels were counted in images of ×20 or ×40 representative high
power fields as previously described [34], and results were recorded as
number of cells or pixels per image. The ImageJ image processing and
analysis program (National Institutes of Health, Bethesda, MD) was
used for all quantitative histomorphometry assessments.
Enzyme-Linked Immunosorbent Assay
For protein extraction, 50 mg of tissue was homogenized using a
motor-driven homogenizer (Kinematica AG, Luzern, Switzerland) in
a 500-μl solution containing 1× phosphate-buffered saline and 1×
protease inhibitor cocktail (Sigma-Aldrich Chemie GmbH, Tauf-
kirchen, Germany). The homogenate was centrifuged at 12,000 rpm
for 20 minutes, at 4°C. The supernatant was collected and used for
further analysis. Total protein in tissue extracts was measured using
the BCA Protein Assay Kit (Thermo Scientific, Rockford, IL). The
concentrations of uPA and active TGF-β1 in tissue extracts were
determined using the commercial ELISA kits Mouse uPA Activity
Assay kit (Innovative Research, Novi, MI) and TGF-β1 Emax
ImmunoAssay System (Promega Corporation, Madison, WI),
respectively. Manufacturers' instructions were followed throughout.Absorbance was measured at 450 nm on an ELISA plate reader
(STAT FAX 2100; Awareness Technology, Inc, Palm City, FL).
Quantitative Gene Expression Analysis
Total RNA was extracted from tissue samples using the
NucleoSpin Total RNA Isolation kit (Macherey-Nagel, Duren,
Germany) according to the manufacturer's instructions. After
spectrophotometric determination of RNA concentration and
quality, samples were stored at −80°C until use. Reverse transcription
was carried out using the PrimeScript 1st strand cDNA synthesis kit
(Takara); manufacturer's instructions were followed throughout. One
microgram of total RNA was used as starting material for cDNA
synthesis. Real-time PCR based on the SYBR Green chemistry was
used to quantitatively analyze the expression of TNF-α, IL-6, IL-10,
TGF-β1, SMAD4, and TGF-β receptor type II (TGF-βRII). The
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control. Primers were designed
using the Primer3 Input software (version 0.4.0), according to
nucleotide sequences available inGenBank (AccessionNos.—TNF-α:
NM_013693, IL-6: NM_031168, IL-10: NM_010548, TGF-β1:
NM_011577, SMAD4: NM_008540, TGF-βRII: NM_009371,
GAPDH: NM_008084). Primer sequences, their positions within
the corresponding genes, and amplicon sizes are presented in Table
W1. PCR amplification was performed in 20-μl reaction mixtures
containing 2 μl of cDNA, 1× KAPA SYBR FAST qPCR master mix
(KAPA BIOSYSTEMS, Woburn, MA), and 150 to 300 nM of each
primer pair (Table W2). The temperature cycling on a Bio-Rad
MiniOpticon System (Bio-Rad Laboratories, Hercules, CA) included
40 cycles consisting of denaturation at 95°C for 10 seconds and
annealing/extension at temperatures ranging from 57 to 63°C for 20
seconds (TableW2). Each PCR reaction was initiated with a 3-minute
denaturation at 95°C and terminated with sequential readings
between 65 and 95°C (increment of 0.5°C) to generate the melting
curve and verify amplicon specificity. For relative quantification of
gene expression, we used the comparative CT method, also known as
the 2−ΔΔCT method [35].
Statistical Analyses
Adenomatous polyp counts were analyzed by the Kruskal-Wallis
one-way analysis of variance and Dunn's post-test. Histomorpho-
metry, relative gene expression, and protein quantification data were
compared between groups using Mann-Whitney U analysis.
Statistical significance was set at P b .05. All analyses were performed
with the GraphPad Prism version 5.0 for windows (GraphPad
Software, San Diego, CA).Results
At 7 Months after DSS Treatment, uPA−/− Mice Develop
Large Sporadic Colorectal Polyps
On necropsy, 7 months after the last episode of experimentally
induced colitis, the only difference observed between experimental
groups was that DSS-treated mice had prominently larger MLN
compared to the untreated controls.When the intestines were cut open,
however, in 5 of the 11 mice, 7 grossly visible, well-sized polyps were
found (FigureW1A). The colonicmucosa exophytic tumors, which had
the typical cornflower-like appearance of colonic polypoid adenomas
(Figure 1A), had sizes ranging from 2 to 10 mm in diameter and were
located either in the descending colon (five of seven) or in the rectum
Figure 1. Pathologic features of uPA−/− + DSS–treated mouse colorectal polypoid adenomas. (A) Gross pathology of a well-formed
colonic polyp found in the descending colon of a uPA−/− + DSS mouse. Normal colon from a WT + DSS mouse is shown below for
comparison. The metric scale included in the images is in centimeters. (B) Overview of a uPA−/− + DSS colonic polyp presenting typical
histopathologic features of tubular adenoma with dense tubular abnormal gland arrangement and cystically dilated mucin-filled glands.
(C) Histomorphologic grading of dysplasia/adenoma lesions contained in polyps. The progression from low-grade dysplasia/adenoma to
high-grade dysplasia/adenoma and CIS is characterized by progressively increased severity of indices of dysplasia including glandular
shape and size irregularities, epithelial pseudostratification, cellular atypia, nuclear size, and pleomorphism and mitotic figures. (D)
Characteristic immunohistochemical features of polypoid adenomas. There is abnormal β-catenin cytoplasmic stabilization with
occasional nuclear translocation. Abnormal epithelia show numerous Ki-67–positive proliferating cells and increased apoptosis
highlighted by caspase-3 labeling. Hematoxylin and eosin (B and C). IHC: DAB chromogen, hematoxylin counterstain (D). Scale bars, 1500
μm (B); 25 μm (C and D; β-catenin and caspase-3); 50 μm (D; Ki-67).
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erosions and microhemorrhages. No grossly detectable polyps were
found in the intestines of uPA−/−, WT, and WT + DSS experimental
groups (uPA−/− + DSS polyps = 7 vs WT + DSS polyps = 0, P b .05;
Figure 1A). This finding suggested that uPA−/− + DSS mice could
model sporadic colorectal polypoid adenomas of humans. To confirm
this, we next characterized the histopathologic and selected immuno-
histochemical features of inflammation-induced polyps.
Histopathologic and Immunohistochemical
Characterization of uPA−/− + DSS Mice Colorectal Polyps
The DSS-induced colorectal polyps of uPA−/− mice had the typical
histopathologic features of colorectal polypoid adenomas that arisespontaneously in humans or after chemically induced carcinogenesis
in mouse models (Figure 1B). All of them were tubular adenomas.
Four of them were broad-based (four of seven) and three were
pedunculated (three of seven). The tumors composed of elongated,
branching, tortuous abnormal crypts, separated by small amounts of
intervening stroma (Figure 1B). Neoplastic gland profiles were
densely packed, with back-to-back positioning and had irregular
shape, which was often angular. They also showed marked variability
in shape and size, slit-shaped lumen, and cystic dilatation (Figures 1,
B and C, and S1B). Occasional dilated crypts were filled with mucin
and exfoliated cells. The neoplastic glands were lined by highly
dysplastic epithelium showing moderate to marked pseudostratifica-
tion, loss of nuclear polarity, cellular pleomorphism, and atypia
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ones (Figure W1C), were abundant (Figures 1, C and D, and W1,
B and C), whereas the most advanced lesions contained increased
apoptotic cells (Figure 1D). On the basis of previously published
histomorphologic criteria, foci of dysplasia/adenoma lesions within
polyps were identified as low-grade dysplasia (LGD) or high-grade
dysplasia (HGD) and carcinoma in situ (CIS, intraepithelial
neoplasia; Figure 1C). All polyps (seven of seven) contained
neoplastic gland foci staged as LGD and HGD. Four polyps also
contained CIS lesions (four of seven). No polyp (zero of seven)
contained early invasive adenocarcinoma lesions, such as neoplastic
gland invasion into the polyp stalk or the underlying submucosa.
Immunohistochemically, the polyps showed abnormal β-catenin
(Figures 1D and W1D) and E-cadherin (Figure W1D) patterns, with
loss of normal cell membrane localization and cytoplasmic
stabilization. Neoplastic glands with CIS lesions also had epithelial
cells with nuclear translocation of β-catenin. TGF-β1 expression
within polyps had no specific pattern. Areas of normal, increased, and
decreased expression co-existed (Figure W1D). LGD and HGD
lesions, however, most often were overexpressing TGF-β1, whereas
occasional HGD and CIS lesions showed a decreased or a complete
loss of positive immunolabeling. The proliferation and apoptosis was
typical for polypoid adenomas with Ki-67– and caspase-3–positive
neoplastic cells being more abundant in HGD and CIS lesions
(Figure 1D).
Distribution of Inflammatory Cells within Polyps
To further characterize the uPA−/− + DSS mouse model of
colorectal neoplasia, we next examined the topographic distribution
of inflammatory cells in the polyps. The major part of the tumor-
associated inflammatory cell infiltrate located in the lamina propria
overlying the muscularis mucosa and the submucosa layer at the base
of the polyp (Figure W2A). Secondarily, inflammatory cells
accumulated in the lamina propria below the surface epithelium of
the polyp and the non-neoplastic epithelium at the peripheral margins
of the polyp. Less inflammatory cells were seen within the tumor
stroma of the main body of the polyps. At the base of the polyp, the
infiltrate consisted of lymphocytes, neutrophils, macrophages, mast
cells, myeloid precursor cells, and plasmacytes (Figure W2A).
Subepithelially, there were mainly macrophages, neutrophils, and
fewer lymphocytes, whereas at the tumor margins there were
macrophages, lymphocytes, and less neutrophils and plasmacytes.
Within the main body of the tumors, there were neutrophils,
macrophages, and occasional lymphocytes.
The immunohistochemical labeling of selected immune cells and
cytokines confirmed the above-mentioned histologic observations
(Figure W2, B–H). The main body of the polyp was infiltrated
primarily by MPO+ neutrophils (Figure W2B) and, to a lesser extent,
by F4/80+ macrophages. At the base of the polyp, there were
numerous MPO+, F4/80+ (Figure W2C), and CD3+ (Figure W2D)
cells. CD3+ T-lymphocytes and Foxp3+ Treg confined at the
periphery of the polyp (Figure W2E) and rarely located between
neoplastic glands, whereas c-kit+ mast cells were almost exclusively
found at the base of the polyp and the underlying submucosa and
muscle layers (Figure W2F). The main sources of IL-17 and IL-6 in
the tumor microenvironment were inflammatory cells located at the
base of the polyp. Specifically, there were IL-6+ macrophages and
neutrophils (Figure W2G) and IL-17+ macrophages and lympho-
cytes (Figure W2H).At 7 Months after DSS Treatment, the Occurrence and
Severity of Epithelial Dysplasia Is Higher in the Colon of
uPA−/− Mice
In addition to the development of polyps, the remaining non-
polypoid colonic epithelium of uPA−/− + DSS mice was given a
significantly higher score for dysplasia compared to WT + DSS mice
(P = .0006). Two of 11 WT + DSS mice had occasional foci of mild
dysplasia, whereas 10 of 11 uPA−/− + DSS mice showed foci of both
mild dysplasia and LGD lesions in their colonic mucosa (excluding
polyps; Figure 2A). The histopathologic and immunohistochemical
characteristics of non-polypoid epithelial dysplastic lesions were
similar to their grade-match counterparts found in the polyps.
Similarly to WT control mice, uPA−/− controls had no dysplastic
lesions in their bowel, indicating that in the absence of inflammatory
stimuli, the deficiency of uPA is not sufficient for colonic
neoplasmatogenesis (Figure 2A).At 7 Months after DSS Treatment, the Colon of
uPA−/− Mice Has More Resident Inflammatory Cells
Seven months after the last cycle of DSS treatment, 5 of 11 uPA−/− +
DSS mice showed a small-sized solitary residual ulcerative lesion in the
last part of the descending colon or in the rectum. This lesion was
absent from WT + DSS mice (0 of 11; Figure W3A). Otherwise, the
colon of both DSS-treated groups had no signs of remaining colitis.
However, the histopathologic score for the presence of resident
inflammatory cells in the colonic mucosa and submucosa (excluding
polyp, dysplastic, and solitary residual ulcerative colitis areas) was
significantly higher in uPA−/− + DSS mice compared to that of WT +
DSS mice (P = .0454; Figure 2A). The uPA−/− and WT untreated
control groups had comparable numbers of colonic resident
inflammatory cells (Figure 2A). Taken together, these results indicate
that 7 months after the DSS-induced episodes of colitis, uPA−/− mice
fail to reduce the numbers of colonic inflammatory cells, as close to the
untreated control baseline levels, as theirWT counterparts. In addition,
uPA deficiency alone, in the absence of colitogenic stimuli, does not
affect residential colonic inflammatory cells. To quantify more
accurately this result, we next performed morphometric counts of
immunohistochemically labeled immune cells.We found that uPA−/− +
DSS mice had significantly more MPO+ neutrophils (P = .0002;
Figure 2B), F4/80+ macrophages (P = .0008; Figure 2B), IL-6+ (P =
.0015; Figure W3B), and IL-17+ (P = .0009; Figure W3B) cells in the
colon and significantly more Foxp3+ Treg in the colon (P = .0046;
Figure 2B) and the MLN (P = .0185; FigureW3C) compared toWT +
DSS mice. By contrast, the total number of CD3+ T-helper
lymphocytes was higher in the colon of WT + DSS mice reaching,
however, no statistical significance (P = .0818; Figure W3B). The
presence of c-kit+ mast cells was unremarkable in both groups. By
comparison to untreated uPA−/− controls, uPA−/− + DSS mice had
significantly higher numbers of both innate and adaptive immunity
cells (Figure 2B). At the same time, residual colonic innate immunity
cells, such as neutrophils and macrophages, of WT + DSS mice
regressed to WT control baseline levels (Figure 2B). The adaptive
immunity colonic mucosa cells, including Treg, however, did not fully
regress (WT vs WT + DSS, P = .048; Figure 2B). This result, which
is in line with gross pathology observation of MLN enlargement at
7 months after DSS treatments, suggests that subtle alterations in local
gut adaptive immunity networks may persist for a particularly long
period after the restoration of colonic mucosa architecture and the
regression of colitis.
Figure 2. Dysplasia and resident inflammatory cells in the non-neoplastic colonic mucosa of mice at 7 months after DSS treatment.
(A) Focal dysplasia in the colonicmucosa of a uPA−/−+DSSmouse (outlined by arrows). Dysplastic glands are readily distinguishable at low
power magnification on the basis of their increased cellularity and loss of goblet cells. At higher magnification, the same dysplastic glands
show the typical features of LGD including increased proliferation (black arrow) and apoptosis (white arrow). Scores for dysplasia (upper
panel) and inflammatory cells (lower panel) were significantly higher in uPA−/− + DSS mice compared to their WT + DSS counterparts.
Despite the absence of colitis, resident inflammatory cells (black arrow in the lower left panel) are more in the otherwise normal non-
neoplastic, non-dysplastic colonic mucosa of a uPA−/− + DSS mouse compared to a topographically matched area of a WT + DSS mouse
(lower right panel). (B) Morphometric counts of immunohistochemically labeled neutrophils (MPO+), macrophages (F4/80+), and Treg
(Foxp3+) provide further evidence that the numbers of immune cells in the colonic mucosa of uPA−/−mice do not regress to baseline
WT + DSS levels at 7 months after colitogenic insult. Hematoxylin and eosin (A). IHC: DAB chromogen, hematoxylin counterstain
(B). Scale bars, 100μm(A, upper left); 50μm(A, lower panel andB, Foxp3); 25μm(A, upper right andB,MPOandF4/80). Numbers on the y-axis
of bar graphs correspond to the means ± SEM of the histologic parameters assessed; *P b .05, **P b .001, ***P b .0001.
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Figure 3. Effects of uPA deficiency in the histopathology of colitis at 1 week after DSS treatment. (A) CIS arising in glands with HGD in
uPA−/− + DSS mouse colitis. Typical LGD from a WT + DSS mouse is shown on the side for comparison. Colitis-associated dysplasia
scores are significantly raised due to deficiency in uPA. (B) The occurrence of the most advanced grades of dysplasia is higher in uPA−/−
mice compared to their WT counterparts. (C) The healing of typical DSS-induced colonic ulcers is retarded due to uPA deficiency.
Consequently, the surface epithelium deficit scores are significantly higher in uPA−/− than in WT mice. (D) In non-ulcerated areas of
colonic mucosa, uPA−/− and WT mice show comparable amounts of inflammatory cell infiltration. Hematoxylin and eosin (A, C, and D).
Scale bars, 50 μm (A); 250 μm (C); 100 μm (D). Numbers on the y-axis of bar graphs correspond to the means ± SEM of histologic scores;
***P b .0001; NS, P N .05.
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Has More Advanced Dysplastic Lesions
In an effort to explain why uPA−/− + DSS mice develop colonic
polypoid adenomas in the long term, while WT + DSS ones do not,
we next examined the colon of mice at the early time point of 1 week
after DSS treatment. We found that WT and uPA−/−controls showed
normal colon histology, whereas their DSS-treated counterparts had
the typical DSS-associated ulcerative colitis. At this early time point,
DSS-treated mice had numerous foci of epithelial dysplasia,
characterized by the same histopathologic and immunohistochemical
features as those described in polyps (Figure 3A). Colonic dysplastic
foci of uPA−/− + DSS mice, however, were in a more advanced stage of
the dysplasia/preneoplasia sequence than those of WT + DSS mice
(P = .0001; Figure 3, A and B). A total of 2-minute polyps were
found in 2 uPA−/− + DSS mice (2 of 24) and 1-minute polyp was
found in the WT + DSS mice (1 of 23). DSS-induced ulcerative
lesions, located mostly at the last part of the descending colon and
the rectum, consistently presented a larger surface epithelium deficit
in the uPA−/− + DSS mice compared to the same lesions of the WT
+ DSS mice (P b .0001; Figure 3C). In the non-ulcerative parts of
the gut mucosa, however, colitis in both groups of DSS-treated mice
was characterized by comparable levels of inflammatory cell
infiltration (P = .1098; Figure 3D).
uPA Deficiency Affects the Colitis Inflammatory Cell
Component at 1 Week after DSS Treatment
To examine whether the tumor-promoting uPA deficiency is
associated with a different inflammatory cell composition of DSS
colitis, we labeled in situ and then quantified selected critical
inflammatory cell types in the colonic mucosa. We found that the
numbers of MPO+ neutrophils were significantly higher in both the
ulcerative lesions (P = .0052; Figure 4A) and the remaining colonic
mucosa (P = .0079; Figure W4A) of uPA−/− + DSS mice compared to
topographically matching areas of WT + DSS mice. The presence of
neutrophils was unremarkable in both uPA−/− and WT untreated
controls (Figure W4A). Likewise, F4/80+ macrophages were signifi-
cantly more in the non-ulcerated colonic mucosa of the uPA−/− + DSS
compared to the WT + DSS mice (P = .0011; Figure 4B). CD3+
lymphocytes, however, were less in the ulcerative lesions (P = .0039;
Figure 4C) and in the colonic lamina propria (P = .0282; Figure
W4B) of uPA−/− + DSS mice than those counted in the corresponding
areas ofWT +DSSmice. In contrast, CD3+ lymphocytes were more in
the colonic mucosa lymphoid follicles of uPA−/− + DSS mice, albeit in
non-statistically significant levels (P = .3642; Figure W4C). Although
comparable numbers of CD3+ cells were identified in the lamina
propria of the normal colonic mucosa of both untreated control groups
(Figure 4C), the lymphoid follicles of uPA−/−mice hadmore CD3+ cells
than their WT counterparts (P = .041; Figure W4C). Having
documented these differences in the CD3+ cell colonic mucosa
population, we next quantified Foxp3+ Treg in four different areas,
including the ulcerative lesions (Figure W4D), the lamina propria
(Figure 4D), and the gut-associated lymphoid tissue (GALT; Figure
W4E) of the colon and the MLN (Figure 4E). The number of Foxp3+
cells was lower in the uPA−/− + DSS compared to the WT + DSS mice,
with difference reaching significance only in the lamina propria (P =
.0282; Figure 4D). Interestingly, in the normal colonic mucosa of the
non–DSS-treated controls, the same comparison had the opposite
outcome (Figure 4D). Specifically, uPA−/− mice had significantly more
Treg than their WT counterparts in all areas examined (lamina propria,P = .0204; GALT, P = .0015; MLN, P = .0433; Figures 4D and W4,
D andE). Finally, c-kit+ mast cells were practically undetectable both in
mice with colitis and in the normal colon of the control groups.uPA Is Upregulated at 1 Week after DSS Treatment
and Its Deficiency Affects the Expression of Cytokines
To confirm previously published results suggesting that uPA is
upregulated in DSS colitis, we assessed uPA protein in the colon
mucosa of mice by ELISA. As expected, WT + DSS mice had
significantly higher levels of uPA than the WT untreated controls
(P = .0023; Figure 5A). Both groups of uPA
−/−
mice showed no
expression of uPA, thus confirming their genetic deficiency. Having
shown that deficiency in uPA affects the inflammatory cell
component of DSS colitis, we next quantified the expression of
selected cytokines with important roles in colitis-associated colon
carcinogenesis by real-time PCR and IHC. We found that the gene
expression of the pro-inflammatory cytokines TNF-α (Figure 5B)
and IL-6 (Figure 5C), as well as the anti-inflammatory cytokine
IL-10 (Figure 5D), was significantly upregulated in uPA
−/−
+ DSS
compared to WT + DSS mice (P = .0303, P = .0079, and P = .0082,
respectively). With IHC, IL-6+ cells were located at the base of
colonic mucosa and within the granular tissue of typical DSS-
induced ulcers (Figure 5E). Morphometric counts of IL-6+ cells
were done in these two areas andwere in accordancewith real-time PCR
quantification of IL-6 expression. IL-6+ cells were significantly more in
uPA
−/−
+ DSS compared to WT + DSS mice in both areas (ulcerative
lesions, P = .0022; lamina propria, P = .0042) (Figure 5E). Likewise, the
pro-inflammatory cytokine IL-17 was also found in higher levels in the
colonic mucosa (P = .0065) and theMLN (P = .0015) of uPA−/− +DSS
mice by IHC(Figure 5F).
The Colon of uPA−/− + DSS Mice Has Low Levels of
Active TGF-β1 Protein at 1 Week after DSS Treatment
Since the active extracellular form of TGF-β1 is a downstream
product of uPA, we next quantified active TGF-β1 in the colon of
mice by ELISA. Untreated uPA−/− had lower levels of active TGF-β1
than untreated WT mice; this difference, however, did not reach
statistical significance (P = .2222). However, uPA−/− + DSS mice had
significantly lower levels in the colon compared to WT + DSS mice
(P = .0079; Figure 6A). To exclude that this was due to reduced
gene expression, we quantitatively determined colonic TGF-β1
expression by real-time PCR. We found that colitis in both uPA−/− +
DSS and WT + DSS mice was characterized by comparable levels of
TGF-β1 expression (Figure 6A). This result was further confirmed
by TGF-β1–specific IHC that detects the total of TGF-β1 protein
without discriminating the active from the latent form (data not
shown). In addition to TGF-β1, the expression of other important
molecules of the TGF-β1 signaling pathway, such as TGF-βRΙΙ and
SMAD4, was also found in comparable levels in both uPA−/− + DSS
and WT + DSS mice (Figure 6, C and D).Discussion
By inducing chemical chronic colitis in uPA−/− mice, we found that
the lack of uPA promotes inflammation-associated colorectal
neoplasia. Compared to their WT counterparts, DSS-treated uPA−/−
mice had an altered colonic mucosa inflammatory milieu and more
advanced epithelial preneoplastic changes that led to the formation of
large colonic adenomatous polyps.
Figure 4. Deficiency in uPA affects the inflammatory cell composition of DSS colitis at 1 week after DSS treatment. (A) Neutrophils
(MPO+) in the granular tissue of ulcers and (B) macrophages (F4/80+) in the lamina propria of colonic mucosa are significantly more in
uPA−/− mice. By contrast, numbers of (C) total T-lymphocytes (CD3+) in colonic ulcers and (D) Treg (Foxp3+) in the lamina propria are
significantly lower due to deficiency in uPA. (E) In the MLN, uPA deficiency correlates with higher numbers of Treg. The difference in
Foxp3+ cell counts, however, reaches significance only in the uPA−/− versus WT untreated control comparison. IHC: DAB chromogen,
hematoxylin counterstain. Scale bars, 25 μm (A, B, and D); 50 μm (C and E). Numbers on the y-axis of bar graphs correspond to the mean
± SEM of immunohistochemically positive cell counts; *P b .05, **P b .001; NS, P N .05.
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poor neoplastic disease prognosis [15]. Consequently, the tumor-
promoting role of uPA in neoplastic cell invasion, growth, and
metastasis has been extensively studied in many different types ofcancer, including colon cancer [15-18,25,26,36]. Except for a few
studies reporting on an antiangiogenic tumor-suppressor effect of
uPA in human patients [37] and syngeneic orthotopic tumor cell
transplant mouse models [37-39], the vast majority of scientific data
Figure 5. uPA is upregulated and its deficiency affects the cytokine milieu of DSS colitis at 1 week after DSS treatment. (A) uPA protein is
significantly upregulated in DSS colitis of WT mice. DSS-treated uPA−/− mice show a significant up-regulation of (B) TNF-α, (C) IL-6, and
(D) IL-10 in comparison with treatment-matchedWT controls. (E) IL-6–specific IHC detects IL-6+ neutrophils in the granular tissue of DSS-
induced mucosal ulcers. In these lesions, as well as in the lamina propria of colonic mucosa, significantly more IL-6+ cells were seen in
uPA−/−+DSS compared toWT+DSSmice. (F) In situ labeling of IL-17 in the MLN of DSS-treated mice. IL-17 is significantly upregulated
both in the MLN and in the colonic mucosa of uPA−/− compared to WT control mice. IHC: DAB chromogen, hematoxylin counterstain (E
and F). Scale bars, 25 μm (E); 50 μm (F). Numbers on the y-axis of bar graphs correspond to the means ± SEM of protein in ng/ml (A);
relative cytokine gene expression (B, C, and D) andmorphometric counts of IHC-positive pixels or cells (E and F). *P b .05, **P b .001, ***P
b .0001.
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that, uPA is widely accepted as a protease of emerging importance in
cancer research [15,17,18]. Yet, its role in the early stages of
carcinogenesis has hardly ever been studied, with the exception of one
study that used the adenomatous polyposis coli–deficient mouse
model (ApcMin/+) of intestinal polyposis [22]. In that study, ApcMin/+
mice, which also lacked the uPA gene, developed less polypoid
adenomas than the ApcMin/+ controls. uPA deficiency, however, did
not affect polyp growth. Furthermore, neoplastic cell proliferation
and vascularization were found to be increased in ApcMin/+uPA−/−
mice [22]. Although these findings agree with our results in that uPA
is not essential for the formation of intestinal adenomatous polyps,
the basic conclusions regarding the role of uPA in colon
carcinogenesis are contradictory. According to that study, the lack
of uPA decreased the frequency of polyps in ApcMin/+ mice, whereas
in our study the lack of uPA led to colitis-associated polyp formation.Fundamental differences between the two mouse models may
account for this discrepancy. One important difference is that in
our DSS colitis model dysplastic and early neoplastic lesions are
caused by inflammation, whereas in the ApcMin/+ model such lesions
develop in the absence of inflammation, due to an intrinsic defect of
theWnt signaling pathway [40]. Interestingly, when ApcMin/+uPA−/−
mice were treated with DSS for just 1 week, the protection, which was
attributed to uPA deficiency, was abolished [22]. This experiment
bridges the seemingly contradictory results of the two studies. Taken
together, all the above suggest that the lack of uPA enhances
colorectal carcinogenesis when the latter arises in an inflammatory
cell/factor–rich environment.
In support to that, we also found a higher percentage of uPA−/− +
DSS mice bearing foci of dysplastic glands in the colon (excluding
polyps) compared to WT + DSS controls at the 7-month time point.
The uPA−/− + DSS dysplastic lesions were in a more advanced stage
Figure 6. Low levels of active TGF-β1 are found in uPA−/−mouse colitis. (A) Active TGF-β1–specific ELISA reveals that under inflammatory
conditions lower levels of active TGF-β1 are being produced in the colonicmucosa of uPA−/−mice. At the gene expression level, however,
(B) TGF-β1 as well as (C) TGF-βRΙΙ and (D) SMAD4 remain unaffected by the lack of uPA. Numbers on the y-axis of bar graphs correspond to
the means ± SEM of protein in ng/ml (A) and relative cytokine gene expression (B, C, and D). *P b .05, **P b .001, ***P b .0001.
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mice. This observation also points out that the lack of uPA promotes the
progression of inflammatory-induced dysplasia to adenoma.
To study the role of uPA in colitis-associated carcinogenesis, we
selected to work with the BALB/c strain of mice, which is not
susceptible to colorectal carcinogenesis with protocols using DSS alone,
i.e., without combining it with carcinogens, such as azoxymethane
[41,42]. In addition, this strain, in contrast to C57BL/6 mice, does not
develop overt chronic colitis after the initial episodes of acute DSS-
induced inflammation [43]. Moreover, the three cycles of 3.5% DSS
applied are known not to be sufficient for inducing colon carcinogenesis
in genetically intact mice [31]. Swiss-Webster and C57BL/6 mice that
are by far the most susceptible strains of mice in that regard need at least
four cycles of 5% DSS administration to develop colon dysplasia and
adenoma [31,44]. Our experimental setting allowed us to clearly
demonstrate that while uPA−/− + DSS mice present sporadic large
colonic polypoid adenomas at 7 months after DSS treatment, their WT
+ DSS counterparts do not. The polyps found arose through the classic
dysplasia to colorectal neoplasia sequence, had the typical colonic
polypoid adenoma histologic features observed in both humans and
mice, and showed evidence of common molecular pathway involve-
ment, including the β-catenin/Wnt and the TGF-β1 [45,46]. For that,
we propose the DSS-treated uPA−/− mice as a novel genetically
engineeredmouse model for studying inflammation-initiated colorectal
neoplasmatogenesis.Selected mouse models of DSS colitis–associated colon cancer have
been reported to develop invasive cancer in a low percentage (10-
25%) several months past DSS treatment. Cancer in these models
arise either from polyps or from flat dysplasia/adenoma lesions
[31,47]. This, however, was not the case in our uPA−/− + DSS mouse
model. At 7 months past DSS treatments, despite exhaustive
histologic sectioning, we found no invasive carcinoma lesions neither
in the flat dysplastic lesions nor in the stalk or the submucosa at the
base of the polyps. Additional studies on uPA−/− mice using more
aggressive DSS treatment protocols or protocols combining DSS with
chemical carcinogens may be necessary to reveal whether adenoma
lesions are able to evolve to carcinoma or if neoplastic cell invasion is
reduced (or even halted) due to uPA deficiency, as other reports
suggest [15,18,24,25,36,48].
To further characterize the uPA−/− + DSS mouse model of
neoplasia, we probed the topographic distribution of selected
inflammatory cell types in the polyps. At 7 months after DSS
treatments, polyps existed in the absence of colitis. Presumptively, the
polyp-associated inflammatory cells represented the tumor-elicited
immune response and were not a remaining component of the DSS-
induced colitis. Our group, as well as others, have previously reported
on the distribution of immune cells in polyps, using classic mouse
models of colon neoplasia, such as the ApcMin/+ [34,49-54] and the
AOM + DSS model [55-57]. The distribution of neutrophils,
macrophages, mast cells, and T-helper lymphocytes, including Treg,
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matches the one described in other mouse models [34,49-57] and
humans [58,59]. This observation suggests that uPA deficiency does
not affect the cellular composition and the distribution of the tumor-
associated inflammatory infiltrate of colonic polyps. The demonstra-
tion of IL-6+ and IL-17+ inflammatory cells at the base of the polyps
supports the recently described roles of these cytokines in tumor
promotion [6,7,9,53,60].
Untreated uPA−/− mice showed no evidence of altered colonic
histology with increasing age. It is concluded that deficiency in uPA
does not affect colonic mucosa homeostasis under normal conditions,
at least until the age of 9 months, which was the end point of our
study. DSS-challenged uPA−/− mice, with the exception of polypoid
adenoma formation and increased colonic gland dysplasia, exhibited a
restored colonic architecture and absence of colitis at 7 months after
treatment. However, compared to treatment-matched WTmice, they
had higher numbers of colonic mucosa resident inflammatory cells,
including neutrophils, macrophages, IL-6+ and IL-17+ cells, and
Treg. This finding suggests that uPA deficiency correlates with an
altered immune response to colitogenic stimuli that persists for a
particularly long period. The up-regulation of immune cells, although
subtle at 7 months after colitis insults, was somewhat surprising, since
uPA−/− mice have been reported to show less inflammatory cells,
impairment in both innate and adaptive immunity, and a decreased
immune response to infection and tissue injury [22,23,61-63].
To more accurately assess the uPA-associated alterations in the
inflammatory response after DSS-induced colonic mucosa injury, we
examined the colon of mice at an early time point after DSS
treatments, i.e., 1 week after the last DSS cycle. We found that DSS-
treated mice presented foci of colonic dysplastic glands, which in the
long term have been reported to evolve to neoplasia through a well-
characterized sequence of events [33,45,46]. We hypothesized that
preneoplastic lesions in the colon of uPA−/− + DSS mice may have
thrived and evolved into well-sized polyps due to a particular tumor-
promoting inflammatory milieu. At 1 week after DSS treatment, we
found that uPA−/− + DSS and WT + DSS mice had numerous
dysplastic lesions in comparable numbers. However, uPA deficiency
significantly correlated with a more advanced grade of the dysplastic
lesions. This finding co-existed with a more robust infiltration of
neutrophils and macrophages and an inflammatory response
characterized by significantly elevated levels of pro-inflammatory
cytokines, such as TNF-α, IL-17, and especially IL-6. The
concomitant elevation of the anti-inflammatory cytokine IL-10 was
evidently unable to downregulate these inflammatory cells and
cytokines, which have been shown to promote carcinogenesis in the
colon and other sites [6,7,9,53,64]. The uPA−/− + DSS mouse colitis
was also different from the one in WT + DSS mice in that it exhibited
less T-lymphocytes in the ulcerative lesions and the remaining colonic
lamina propria and more in the organized lymphoid tissue of the
bowel. Likewise, the Foxp3+ suppressive subset of T-lymphocytes
(Treg) followed a similar pattern. This finding suggests that T-lymphocytes
and Treg accumulate in the organized lymphoid bowel tissue andMLN of
uPA−/− + DSS mice, but their translocation in the damaged mucosa is
retarded. This is probably due to their reduced mobility because of the
altered cell–extracellular matrix interactions caused by the lack of uPA-
mediated proteolysis [11,61].
Our findings regarding Treg are interesting, given the debated role
of this immune-suppressive subset of lymphocytes in carcinogenesis
[53,65,66]. Indeed, the roles of Treg in cancer appear paradoxical.Studies correlating high densities of tumor-associated Treg with poor
prognosis in several types of human cancers are now challenged by
studies on the same types of cancer demonstrating correlation with
longer survival of patients [67-72]. Likewise, data from mouse
models indicating that Treg, which accumulate in developing
tumors, function mainly to suppress protective antineoplastic
immune responses [66,73] are challenged by our studies in mice
that show that the adoptive transfer of Treg not only protects but is
also capable of diminishing already established intestinal, breast, and
prostate cancers [33,49-53,64,74]. In the present study, we find that
both uPA−/− DSS–treated and untreated mice have significantly
more Treg in their GALT compared to their WT controls. This
agrees with the results of a recent study that elegantly dissects
previously unknown associations of uPA and Treg homeostasis. This
study demonstrates that uPA−/− mice are characterized by increased
Treg development, yet impaired Treg suppressive function [75].
These results, along with the observations of recent studies, which
show that the capacity of Treg to suppress or promote carcinogenesis
depends on their activation status [52,67,74], suggest that the
impaired function of Treg in uPA−/− mice may, at least in part,
contribute to their susceptibility in inflammatory-associated colon
carcinogenesis.
This susceptibility, however, may also have another more
straightforward explanation. Indeed, uPA−/− + DSS mice had more
extensive ulcerative lesions than WT + DSS mice. In the DSS model
of colitis, this translates to a more robust inflammatory response, since
the delayed restoration of colon epithelial integrity retains the
exposure of gut mucosa immune system elements in gut flora
antigenic stimuli. The delayed ulcer re-epithelialization of uPA−/−
mice observed in our study at 1 week after DSS treatment reflects the
decreased wound healing rate of this mouse model [14,76,77]. The
profound up-regulation of uPA in the intestines of humans with
inflammatory bowel disease [78,79] and DSS-treated rodents
[80,81], which was also confirmed in the present study, indicates
that uPA is involved in gut mucosa ulcer healing. The full restoration
of bowel mucosa architecture at 7 months after DSS-induced injury,
despite the occasional presence of some remaining solitary small ulcers
in the rectum, suggests that uPA deficiency impairs but not fully
hampers the colon mucosa healing capacity in mice.
Given that TGF-β1 extracellular activation depends, in a
considerable degree, on uPA proteolytic function [14,27,28], we
also assessed selective elements of the TGF-β1 pathway in uPA−/−
mice.We found that the gene expression levels of TGF-β1, its receptor
TGF-βRΙΙ, and the key downstream transcription factor of TGF-β1
signaling SMAD4 [2,29,45] were similar in both uPA−/− + DSS and
WT +DSS–treated mice. This finding shows that uPA deficiency does
not affect the TGF-β1 pathway at the gene expression level. However,
using an ELISA that specifically detects the active form of TGF-β1, we
found that uPA deficiency significantly lowered the presence of the
extracellular active TGF-β1 in the inflamed colonic mucosa.
Untreated uPA−/− mice also had lower levels of active TGF-β1
compared to their WT counterparts, but this difference was not
significant and less pronounced compared to the one seen in DSS-
treated mice. This indicates that under normal conditions, low levels
of active TGF-β1 produced by cleavage of its latent form by other
non–uPA-related proteases [28] may suffice for preserving gut health.
Normal TGF-β1 signaling is important in preserving the
homeostasis of colonic epithelium and suppressing early neoplasia
through antiproliferating signals. At a later stage of neoplastic
186 uPA Deficiency and Colonic Adenomas Karamanavi et al. Translational Oncology Vol. 7, No. 2, 2014evolution, however, TGF-β1 has been shown to promote invasion
and metastasis [2,29,45,82]. An intact TGF-β1 is also needed for the
appropriate regulation of immune responses and wound healing [83].
Taken together, these data suggest that the inability of uPA−/− mice to
produce adequate amounts of the extracellularly cleaved biologically
active form of TGF-β1 may have contributed to their increased risk
for colon tumorigenesis at many different levels, involving early
neoplastic cell evolution, inflammation, and impaired wound healing.
This finding also highlights the fact that the studying of the
tumorigenic corruptions of the TGF-β1 signaling pathway should not
only focus at the gene level but also expand to the extracellular events
leading to the generation of the active TGF-β1.
The results of this study challenge the current notion according to
which uPA is viewed solely as a tumor promoter. Instead, they suggest
that uPA may act as a tumor suppressor in the early stages of
inflammation-associated colon carcinogenesis. Importantly, they also
show that the lack of a single protease in the environment of colonic
epithelial preneoplastic lesions, which develop due to episodes of
colitis, may determine whether these lesions will progress to neoplasia
in due time.
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Primer Sequence (5′-3′) Positions 1 Amplicon Size (bp)
TNF-α (F) ACGTCGTAGCAAACCACCAA 437-456 146
TNF-α (R) GAGAACCTGGGAGTAGACAAGG 561-582
IL-6 (F) GGATACCACTCCCAACAGACC 142-162 144
IL-6 (R) TCTGCAAGTGCATCATCG 268-285
IL-10 (F) TTCCCTGGGTGAGAAGCTGAA 405-425 140
IL-10 (R) CCTTGTAGACACCTTGGTCTTGG 522-544
TGF-β1 (F) GGAGAGCCCTGGATACCAAC 1697-1716 149
TGF-β1 (R) GCAGGGTCCCAGACAGAAG 1810-1829
SMAD4 (F) CCATATCACTATGAGCGGGTTG 828-849 144
SMAD4 (R) CGAATGTCCTTCAGTGGGTAAG 950-971
TGF-βRII (F) CTTGCGACAACCAGAAGTCC 580-599 131
TGF-βRII (R) GTCGTGGCAAACCGTCTC 693-710
GAPDH (F) TGTGTCCGTCGTGGATCTGA 761-780 150
GAPDH (R) TTGCTGTTGAAGTCGCAGGAG 890-910
1 According to gene sequences with the following GenBank Accession Nos.: TNF-α—NM_013693, IL6—NM_031168, IL10—NM_010548, TGF-β1—NM_011577, SMAD4—NM_008540, TGF-βRII—
NM_009371, GAPDH—NM_008084.Table W2. Concentrations and annealing temperatures of the primers used for gene expression analysis.








Figure W1. Pathologic features of the uPA−/− + DSS–treated mouse model of colorectal neoplasia. (A) Macroscopic appearance of the
seven mouse polyps found in the uPA−/− + DSS experimental group. HGD in polypoid adenomas is typified by (B) back-to-back
positioning of angular glands that differ in size and shape, marked pseudostratification of neoplastic epithelia, loss of epithelial cell
nuclear polarity, numerous mitotic figures, and (C) nuclear pleomorphism and abnormal mitoses (arrow). (D) β-Catenin abnormal staining
patterns sharply demarcate neoplastic glands in a colonic polyp. Neoplastic epithelia also show abnormal cytoplasmic stabilization of E-
cadherin and increase or loss of TGF-β1 expression. Hematoxylin and eosin (B and C). IHC: DAB chromogen, hematoxylin counterstain
(D). Scale bars, 50 μm (B and D; E-cadherin); 25 μm (C); 100 μm (D; β-catenin and TGF-β1).
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Figure W2. Aspects of the topographic distribution of inflammatory cells in the uPA−/− + DSS mouse polyps. (A) Dense inflammatory
infiltrate at the base of a mouse polyp consisting of all types of different immune cells, including mast cells (black arrowhead) and myeloid
precursor cells (white arrowhead). Immune cell–specific IHC is used to demonstrate MPO+ neutrophils (B), F4/80+ macrophages (C),
CD3+ lymphocytes (D), c-kit–positive mast cells (F), and IL-6+ (G) and IL-17+ (H) cells at the base of the mouse polyps. A Foxp3+ Treg
infiltrate located at the lateral margins of the neoplastic tissue is also shown (E). Hematoxylin and eosin (A). IHC: DAB chromogen,
hematoxylin counterstain (B–H). Scale bars, 25 μm (A); 100 μm (B–D, G, and H); 50 μm (E and F).
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FigureW3. Histopathologic features of mouse colon and immune cell counts of DSS-treated groups at 7 months after DSS treatment. (A)
Residual ulcerative lesions with necrotic tissue debris on the surface persist in the rectum of DSS-treated uPA−/− mice. WT mice at 7
months after the last cycle of DSS administration show a completely restored rectal mucosa architecture. (B) Morphometric immune cell
count comparison in the lamina propria of colonic mucosa. DSS-treated uPA−/− mice have significantly more IL-6+ and IL-17+ cells
compared to WT + DSS mice. CD3+ cells are less in uPA−/− mice, although the difference from the WT controls is not statistically
significant. (C) The MLN of the uPA−/− mice bear significantly higher numbers of Foxp3+ Treg. Hematoxylin and eosin (A). IHC: DAB
chromogen, hematoxylin counterstain (C). Scale bars, 50 μm (A); 25 μm (C). Numbers on the y-axis of bar graphs correspond to the means
± SEM of cell counts.
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Figure W4. Immune cell counts in the colon of mice at 1 week after DSS treatment. In the lamina propria of colonic mucosa, uPA−/− +
DSS mice have more (A) neutrophils (MPO+) and (B) less T-lymphocytes (CD3+) in comparison with WT + DSS mice. (C) In mucosal
lymphoid follicles, uPA deficiency associates with increased numbers of T-lymphocytes in both DSS-treated and non-treated group
comparisons. (D) Foxp3+ Treg counts in ulcerative lesions and (E) GALT yield a non-statistically significant difference between uPA−/−+
DSS andWT+DSSmice. uPA−/− untreated control mice, however, have significantly more Treg than theWT untreatedmice in the GALT.
Numbers on the y-axis of bar graphs correspond to the means ± SEM of cell counts.
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